Hamilton-based biopharmaceutical firm Kiniksa Pharmaceuticals is dedicated to finding, acquiring, developing and distributing therapeutic drugs aimed at treating patients suffering from debilitating diseases around the world. Its product portfolio includes ARCALYST, which targets heart disorder pericarditis; Mavrilimumab, a monoclonal antibody inhibitor for giant cell arteritis; Vixarelimab, a monoclonal antibody for chronic skin inflammation; and KPL-404, a monoclonal antibody inhibitor that targets CD40-CD154 interaction. Established in 2015, the company's mission is to meet significant unmet medical needs in the market.
Kiniksa Pharmaceuticals, Ltd.'s ticker is KNSA
The company's shares trade on the NASDAQ stock exchange
They are based in Lexington, Massachusetts
There are 51-200 employees working at Kiniksa Pharmaceuticals, Ltd.
It is https://www.kiniksa.com/
Kiniksa Pharmaceuticals, Ltd. is in the Healthcare sector
Kiniksa Pharmaceuticals, Ltd. is in the Biotechnology industry
The following five companies are Kiniksa Pharmaceuticals, Ltd.'s industry peers: